Table 1. Patient demographics. None of the patients in this cohort had myeloid sarcoma; secondary and therapy-related acute myeloid leukemia patients were not included. Cytogenetic data were not available for two patients.

Patient demographics
De novo AML (n = 250)	Median (range)
Age	42.5 years (15–78 years)
Sex	Males: 156, females: 94
Total WBC	15,400/cu mm (166–480,000)
Platelet count	32,000/cu mm (4000–486,000)
Hb	8.2 mg% (3–18)
Blast%	68% (21–100)
LDH	850 U/l (206–9963)
Creatinine	1 mg% (0.54–4.7)
WHO classification (n = 250)
AML with recurrent genetic abnormalities	101 (40.4%)
AML with MDS-related features	44 (17.6%)
AML not otherwise specified	105 (42.0%)
Cytogenetic risk group (n = 248)
Favorable	27 (10.9%)
Intermediate	144 (58.1%)
Adverse	77 (31.0%)
Normal karyotype	112 (45.1%)
Molecular markers
NPM1 mutation (n = 245)	79 (32.3%)
FLT3-ITD (n = 245)	43 (17.55%)
FLT3-TKD (n = 244)	10 (4.3%)
t (8:21) (RUNX1-RUNX1T1) (n = 244)	20 (8.9%)
inv 16 (CBFB-MYH11) (n = 244)	11 (4.7%)